Navigation Links
Cornerstone Pharmaceuticals' Cancer Metabolism Inhibitor, CPI-613, Showing Promise in Phase I Trial for Acute Myeloid Leukemia
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Cornerstone Pharmaceuticals today announced its first-in-class cancer metabolism inhibitor drug will be featured in a poster session at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH).  Findings from the study (http://bit.ly/scSBqO) will be presented along with preclinical findings at ASH from a Phase I clinical trial of CPI-613 in refractory acute leukemias. In August 2011, CPI-613 received FDA orphan drug designation for the treatment of acute myeloid leukemia (AML).

CPI-613 is the subject of a Phase I clinical single agent trial to evaluate safety, tolerability, maximum tolerated dose, efficacy, and pharmacokinetics for patients with relapsed and refractory hematologic malignancies. To date, eleven patients have been treated with at least one cycle of CPI-613. Interim clinical data suggests that altered lipid and mitochondrial metabolism are viable targets in acute leukemias. CPI-613 is a novel agent that has activity against several acute leukemia cell lines in vitro and in vivo and demonstrates activity in patients with relapsed AML and Myelodysplastic Syndrome (MDS). Several patients experienced significant clinical benefit, including a sustained complete remission when treated with CPI-613 as a single agent.  Only minor toxicities were observed.

According to the National Cancer Institute, one in 77 men and women will be diagnosed with leukemia during their lifetime. In adults these diseases disproportionally affect the elderly with a median age of onset of 72 for acute myeloid leukemia. Patients over the age of 60 have less than 10 percent survival at five years. It is estimated that 12,950 Americans (6,830 men and 6,120 women) will be diagnosed with acute myeloid leukemia in 2011. Chemotherapy is the standard of treatment for untreated adult.  Cornerstone's CPI-613 may represent a potential new alternative treatment for this disease.

"This study demonstrates early proof of concept for this class of agents, which is very important because relatively few treatment options exist for patients with myeloid leukemia, especially with relapsed/refractory disease," said the CEO of Cornerstone Pharmaceuticals, Robert Shorr, Ph.D. "Preliminary results from the ongoing Phase I study demonstrate the safety of this first-in-class agent, CPI-613, with very few adverse events, and support further exploration of CPI-613 as a potential treatment for AML and other hematologic malignancies."

The CPI-613 poster session, "Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia" (http://bit.ly/scSBqO) is scheduled for December 12 from 6 p.m. to 8 p.m. at Hall GH (San Diego Convention Center).

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and not present in normal cells. Patients with solid tumors and hematologic cancers are currently being treated in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have failed all other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer and for AML.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713
news@cornerstonepharma.com

 


'/>"/>
SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
3. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
6. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
9. Cornerstone Therapeutics Announces Collaboration with The Cough Company
10. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
11. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):